IL13RA2 and neoplasm: By bridging IL-13Rα2+ tumor cells and CD3ε on T cells, the BiTE induces T-cell activation (CD69/CD25 upregulation), GZMB release, and production of inflammatory cytokines (IFN-γ, TNF-α), culminating in tumor-specific lysis.